148 related articles for article (PubMed ID: 22450744)
1. p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway.
Ozenne P; Dayde D; Brambilla E; Eymin B; Gazzeri S
Oncogene; 2013 Feb; 32(8):1050-8. PubMed ID: 22450744
[TBL] [Abstract][Full Text] [Related]
2. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
3. Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers.
Saito K; Takigawa N; Ohtani N; Iioka H; Tomita Y; Ueda R; Fukuoka J; Kuwahara K; Ichihara E; Kiura K; Kondo E
Mol Cancer Ther; 2013 Aug; 12(8):1616-28. PubMed ID: 23761220
[TBL] [Abstract][Full Text] [Related]
4. Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival.
Dayde D; Guerard M; Perron P; Hatat AS; Barrial C; Eymin B; Gazzeri S
Oncogene; 2016 Jul; 35(30):3986-94. PubMed ID: 26686095
[TBL] [Abstract][Full Text] [Related]
5. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells.
Akca H; Tani M; Hishida T; Matsumoto S; Yokota J
Lung Cancer; 2006 Oct; 54(1):25-33. PubMed ID: 16872715
[TBL] [Abstract][Full Text] [Related]
6. Activation of the signal transducer and activator of transcription 3 pathway up-regulates estrogen receptor-beta expression in lung adenocarcinoma cells.
Wang HC; Yeh HH; Huang WL; Lin CC; Su WP; Chen HH; Lai WW; Su WC
Mol Endocrinol; 2011 Jul; 25(7):1145-58. PubMed ID: 21546410
[TBL] [Abstract][Full Text] [Related]
7. EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.
Clay TD; Russell PA; Do H; Sundararajan V; Conron M; Wright GM; Solomon B; Dobrovic A; McLachlan SA; Moore MM
Med Oncol; 2017 Sep; 34(10):175. PubMed ID: 28879441
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.
Gao SP; Mark KG; Leslie K; Pao W; Motoi N; Gerald WL; Travis WD; Bornmann W; Veach D; Clarkson B; Bromberg JF
J Clin Invest; 2007 Dec; 117(12):3846-56. PubMed ID: 18060032
[TBL] [Abstract][Full Text] [Related]
9. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Zhang X; Belkina N; Jacob HK; Maity T; Biswas R; Venugopalan A; Shaw PG; Kim MS; Chaerkady R; Pandey A; Guha U
Proteomics; 2015 Jan; 15(2-3):340-55. PubMed ID: 25404012
[TBL] [Abstract][Full Text] [Related]
10. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
[TBL] [Abstract][Full Text] [Related]
11. ARF promotes the degradation of the Epidermal Growth Factor Receptor by the lysosome.
Beaumont A; Dayde D; Hatat AS; Barrial C; Perron P; Eymin B; Gazzeri S
Exp Cell Res; 2018 Sep; 370(2):264-272. PubMed ID: 29959911
[TBL] [Abstract][Full Text] [Related]
12. Correction to: p14
Ozenne P; Dayde D; Brambilla E; Eymin B; Gazzeri S
Oncogene; 2021 May; 40(20):3633-3634. PubMed ID: 33947964
[No Abstract] [Full Text] [Related]
13. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.
Hemmati PG; Gillissen B; von Haefen C; Wendt J; Stärck L; Güner D; Dörken B; Daniel PT
Oncogene; 2002 May; 21(20):3149-61. PubMed ID: 12082630
[TBL] [Abstract][Full Text] [Related]
14. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
[TBL] [Abstract][Full Text] [Related]
15. STAT3 expression in activating EGFR-driven adenocarcinoma of the lung.
Takata S; Takigawa N; Segawa Y; Kubo T; Ohashi K; Kozuki T; Teramoto N; Yamashita M; Toyooka S; Tanimoto M; Kiura K
Lung Cancer; 2012 Jan; 75(1):24-9. PubMed ID: 21684622
[TBL] [Abstract][Full Text] [Related]
16. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway.
Tsai MF; Chang TH; Wu SG; Yang HY; Hsu YC; Yang PC; Shih JY
Sci Rep; 2015 Sep; 5():13574. PubMed ID: 26338423
[TBL] [Abstract][Full Text] [Related]
17. V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors.
Matsushima S; Ohtsuka K; Ohnishi H; Fujiwara M; Nakamura H; Morii T; Kishino T; Goto H; Watanabe T
J Thorac Oncol; 2014 Sep; 9(9):1377-84. PubMed ID: 25057940
[TBL] [Abstract][Full Text] [Related]
18. Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma.
Makino Y; Yoon JH; Bae E; Kato M; Miyazawa K; Ohira T; Ikeda N; Kuroda M; Mamura M
Biochem Biophys Res Commun; 2017 Mar; 484(2):269-277. PubMed ID: 28115165
[TBL] [Abstract][Full Text] [Related]
19. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.
Maity TK; Venugopalan A; Linnoila I; Cultraro CM; Giannakou A; Nemati R; Zhang X; Webster JD; Ritt D; Ghosal S; Hoschuetzky H; Simpson RM; Biswas R; Politi K; Morrison DK; Varmus HE; Guha U
Cancer Discov; 2015 May; 5(5):534-49. PubMed ID: 25735773
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis by morusin in human non-small cell lung cancer cells by suppression of EGFR/STAT3 activation.
Park HJ; Min TR; Chi GY; Choi YH; Park SH
Biochem Biophys Res Commun; 2018 Oct; 505(1):194-200. PubMed ID: 30243717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]